1. Beier HM, Spitz IM: Progesterone Antagonists in Reproductive Medicine and Oncology. Oxford University Press, Cambridge, UK, 1994
2. Klijn JGM, Setyono-Han B, Sander HJ, Lamberts SWJ, deJong FH, Deckers GH, Foekens JA: Preclinical and clinical treatment of breast cancer with antiprogestins. In: Beier HM, Spitz IM (eds) Progesterone Antagonists in Reproductive Medicine and Oncology. Oxford University Press, Cambridge, UK, 1994, pp 181–189
3. Horwitz KB: The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13: 146–163, 1992
4. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B: Phase II study of the progesterone antagonist mifepristone (RU 486) in patients with untreated metastatic breast carcinoma. A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14: 2709–2712, 1996
5. Robertson JFR, Willsher P, Blamey RW: Onapristone, a progesterone receptor antagonist, as first line endocrine therapy in primary breast cancer (Abstract 515). Breast Cancer Res Treat 41: 288, 1996